The Inflammatory Bowel Diseases Research Group (GReMII, from its Catalan name Grup de Recerca en Malalties Inflamatòries Intestinals) is a multidisciplinary group led from the clinical side by Dr Eugeni Domènech, head of the Gastroenterology & Hepatology Department and the Inflammatory Bowel Diseases (IBD) Unit at Germans Trias i Pujol University Hospital (HUGTiP) and by Dr Josep Manyé Almero, Principal Investigator for Basic and Translational Research. The group is part of the CIBER Consortium (Spanish Ministry of Science) as well as part of the IBDomics and ENEIDA Consortium for genomic research in immune-mediated inflammatory diseases, of which Dr Domènech is the coordinator.

GReMII has conducted cutting-edge research over the last 30 years, integrating clinical and translational reseach. Thus, it has positioned itself as a national and international leader in holistic care for IBD patients, resulting in its recognition and excellence certification by the Ad Qualitatem Foundation. Lately, the group has initiated innovative research aimed at solving the severe and recurrent complications associated with both ulcerative colitis and Crohn's disease (CD). Understanding, innovating, explaining and training are important and integrated parts of our scientific task with a view to transferring our results to clinical practice. The team combines experts in different skills to ensure that research questions are tackled from the most experimental side (IGTP) to the most clinical side (HUGTiP). The research lines are based on innovative research tools, which allow us to generate new hypotheses aimed at the development of a more personalized medicine, better therapies and improved patient management.

Keywords: Ulcerative colitis, Crohn's disease, epitranscriptomic biomarkers, corticorefractoriness, postoperative recurrence, creeping fat as a therapeutic target.